A Phase I Study Using Submyeloablative Dosing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Busulfan (Primary)
- Indications CNS cancer
- Focus Adverse reactions
- 05 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 15 Jun 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 11 Feb 2009 New trial record